TP53 and cancer: Due to the well-known consequences of the cytoplasmic mortalin-p53 interaction, for instance, the contribution to the malignant transformation of NIH/3T3 cells (Wadhwa et al., 1999) and the life span extension of the human diploid fibroblast MRC-5 leading to a non-permanent escape from cellular senescence (Kaula et al., 2000), abrogation of this interaction as an anti-cancer therapeutic concept emerged (Wadhwa et al., 2000; Wadhwa et al., 2002).